Zhejiang Hisoar Stock Hits Day Low of CNY 7.40 Amid Price Pressure

Zhejiang Hisoar Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 6.76% and reaching an intraday low of CNY 7.40. This performance stands in contrast to the China Shanghai Composite, which fell by only 1.26% on the same day. Over the past week, the stock has decreased by 2.87%, while it has shown a more positive trend over the past month with a gain of 7.66%. Despite this recent uptick, the company's long-term performance metrics raise concerns. Over the last five years, net sales have declined at an annual rate of 6.39%, and operating profit has seen a drastic decrease of 180.98%. The company's return on capital employed is notably low at 2.16%, indicating challenges in generating profitability from its capital investments. Zhejiang Hisoar's market capitalization stands at CNY 11,906 million, categorizing it as a large-cap company. However, its debt-equity ratio is concerning at 0.01, and the return on equity is negative at -2.17%. These factors contribute to a complex financial landscape for the company as it navigates current market conditions.